Discontinued — last reported Q4 '24
EBIT at other companies
Other financials
Where this comes from
Calculated from Summit Therapeutics’s reported figures.
The official record: Summit Therapeutics’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's EBIT?
- Summit Therapeutics (SMMT) reported EBIT of -$65.61M in Q4 2024.
- How has Summit Therapeutics's EBIT changed year-over-year?
- Summit Therapeutics's EBIT decreased by 81.2% year-over-year, from -$36.21M to -$65.61M.
- What is the long-term trend for Summit Therapeutics's EBIT?
- Over 3 years (2021 to 2024), Summit Therapeutics's EBIT has grown at a 37.9% compound annual growth rate (CAGR), from -$86.19M to -$226M.
- What does EBIT mean?
- Profit before interest and taxes — the business's core earning power.
- How do you interpret EBIT?
- Higher is better. Because it adds back interest, EBIT compares earning power across firms with very different debt loads — the base for interest coverage and the EV/EBIT multiple. For filers reporting operating income it equals that line, excluding non-operating swings.
- How does EBIT compare across companies?
- Comparable across companies regardless of leverage or tax domicile; the standard 'earning power' line for cross-company analysis. Least meaningful for banks and insurers.